Search Results - "Pao, William"

Rational, biologically based treatment of EGFR -mutant non-small-cell lung cancer by Pao, William, Chmielecki, Juliann

“…Key Points Epidermal growth factor receptor ( EGFR )-mutant tumours define a unique subset of non-small-cell lung cancer (NSCLC). These tumours display…”
Get full text

New driver mutations in non-small-cell lung cancer by Pao, William, Dr, Girard, Nicolas, MD

“…Summary Treatment decisions for patients with lung cancer have historically been based on tumour histology. Some understanding of the molecular composition of…”
Get full text

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor–Resistant Disease by Ohashi, Kadoaki, Maruvka, Yosef E, Michor, Franziska, Pao, William

“…EGFR-mutant lung cancer was first described as a new clinical entity in 2004. Here, we present an update on new controversies and conclusions regarding the…”
Get full text

How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers by POLITI, Katerina, PAO, William

“…Genetically engineered mouse models (GEMMs) of human cancer were first created nearly 30 years ago. These early transgenic models demonstrated that mouse cells…”
Get full text

Epidermal growth factor receptor mutation testing in lung cancer: searching for the ideal method by Pao, William, Ladanyi, Marc

Get full text

New Strategies in Overcoming Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Lung Cancer by OXNARD, Geoffrey R, ARCILA, Maria E, CHMIELECKI, Juliann, LADANYI, Marc, MILLER, Vincent A, PAO, William

“…The management of non-small cell lung carcinoma (NSCLC) has been transformed by the observation that lung adenocarcinomas harboring mutations in epidermal…”
Get full text

Anchored multiplex PCR for targeted next-generation sequencing by Zheng, Zongli, Liebers, Matthew, Zhelyazkova, Boryana, Cao, Yi, Panditi, Divya, Lynch, Kerry D, Chen, Juxiang, Robinson, Hayley E, Shim, Hyo Sup, Chmielecki, Juliann, Pao, William, Engelman, Jeffrey A, Iafrate, A John, Le, Long Phi

“…Scalable and rapid target enrichment method for next-generation sequencing of clinical-grade, formalin-fixed paraffin-embedded cancer samples. We describe a…”
Get full text

Design of Helical Capacitance Sensor for Holdup Measurement in Two-Phase Stratified Flow: A Sinusoidal Function Approach by Lim, Lam Ghai, Pao, William K S, Hamid, Nor Hisham, Tang, Tong Boon

“…A 360° twisted helical capacitance sensor was developed for holdup measurement in horizontal two-phase stratified flow. Instead of suppressing nonlinear…”
Get full text

RET Fusions Define a Unique Molecular and Clinicopathologic Subtype of Non–Small-Cell Lung Cancer by Wang, Rui, Hu, Haichuan, Pan, Yunjian, Li, Yuan, Ye, Ting, Li, Chenguang, Luo, Xiaoyang, Wang, Lei, Li, Hang, Zhang, Yang, Li, Fei, Lu, Yongming, Lu, Qiong, Xu, Jie, Garfield, David, Shen, Lei, Ji, Hongbin, Pao, William, Sun, Yihua, Chen, Haiquan

“…The RET fusion gene has been recently described in a subset of non-small-cell lung cancers (NSCLCs). Because we have limited knowledge about these tumors, this…”
Get full text

Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non–Small-Cell Lung Cancer: Current Knowledge and Future Directions by PAO, William, MILLER, Vincent A

“…Gefitinib and erlotinib are small molecules that selectively inhibit epidermal growth factor receptor (EGFR) tyrosine kinase activity. When these drugs were…”
Get full text

Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs by Kris, Mark G, Johnson, Bruce E, Berry, Lynne D, Kwiatkowski, David J, Iafrate, A. John, Wistuba, Ignacio I, Varella-Garcia, Marileila, Franklin, Wilbur A, Aronson, Samuel L, Su, Pei-Fang, Shyr, Yu, Camidge, D. Ross, Sequist, Lecia V, Glisson, Bonnie S, Khuri, Fadlo R, Garon, Edward B, Pao, William, Rudin, Charles, Schiller, Joan, Haura, Eric B, Socinski, Mark, Shirai, Keisuke, Chen, Heidi, Giaccone, Giuseppe, Ladanyi, Marc, Kugler, Kelly, Minna, John D, Bunn, Paul A

“…IMPORTANCE Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung…”
Get full text

ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers by BERGETHON, Kristin, SHAW, Alice T, MARK, Eugene J, BATTEN, Julie M, HAIQUAN CHEN, WILNER, Keith D, KWAK, Eunice L, CLARK, Jeffrey W, CARBONE, David P, HONGBIN JI, ENGELMAN, Jeffrey A, MINO-KENUDSON, Mari, IGNATIUS OU, Sai-Hong, PAO, William, IAFRATE, A. John, KATAYAMA, Ryohei, LOVLY, Christine M, MCDONALD, Nerina T, MASSION, Pierre P, SIWAK-TAPP, Christina, GONZALEZ, Adriana, RONG FANG

“…Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene have recently been described in a subset of non-small-cell lung cancers (NSCLCs)…”
Get full text

Heterogeneous Mechanisms of Primary and Acquired Resistance to Third-Generation EGFR Inhibitors by Ortiz-Cuaran, Sandra, Scheffler, Matthias, Plenker, Dennis, Dahmen, Llona, Scheel, Andreas H, Fernandez-Cuesta, Lynnette, Meder, Lydia, Lovly, Christine M, Persigehl, Thorsten, Merkelbach-Bruse, Sabine, Bos, Marc, Michels, Sebastian, Fischer, Rieke, Albus, Kerstin, König, Katharina, Schildhaus, Hans-Ulrich, Fassunke, Jana, Ihle, Michaela A, Pasternack, Helen, Heydt, Carina, Becker, Christian, Altmüller, Janine, Ji, Hongbin, Müller, Christian, Florin, Alexandra, Heuckmann, Johannes M, Nuernberg, Peter, Ansén, Sascha, Heukamp, Lukas C, Berg, Johannes, Pao, William, Peifer, Martin, Buettner, Reinhard, Wolf, Jürgen, Thomas, Roman K, Sos, Martin L

“…To identify novel mechanisms of resistance to third-generation EGFR inhibitors in patients with lung adenocarcinoma that progressed under therapy with either…”
Get full text

AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer by Cross, Darren A E, Ashton, Susan E, Ghiorghiu, Serban, Eberlein, Cath, Nebhan, Caroline A, Spitzler, Paula J, Orme, Jonathon P, Finlay, M Raymond V, Ward, Richard A, Mellor, Martine J, Hughes, Gareth, Rahi, Amar, Jacobs, Vivien N, Red Brewer, Monica, Ichihara, Eiki, Sun, Jing, Jin, Hailing, Ballard, Peter, Al-Kadhimi, Katherine, Rowlinson, Rachel, Klinowska, Teresa, Richmond, Graham H P, Cantarini, Mireille, Kim, Dong-Wan, Ranson, Malcolm R, Pao, William

“…First-generation EGFR tyrosine kinase inhibitors (EGFR TKI) provide significant clinical benefit in patients with advanced EGFR-mutant (EGFRm(+)) non-small…”
Get more information

SFK/FAK Signaling Attenuates Osimertinib Efficacy in Both Drug-Sensitive and Drug-Resistant Models of EGFR-Mutant Lung Cancer by Ichihara, Eiki, Westover, David, Meador, Catherine B, Yan, Yingjun, Bauer, Joshua A, Lu, Pengcheng, Ye, Fei, Kulick, Amanda, de Stanchina, Elisa, McEwen, Robert, Ladanyi, Marc, Cross, Darren, Pao, William, Lovly, Christine M

“…Mutant-selective EGFR tyrosine kinase inhibitors (TKI), such as osimertinib, are active agents for the treatment of -mutant lung cancer. Specifically, these…”
Get full text

Clinical Definition of Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non–Small-Cell Lung Cancer by JACKMAN, David, PAO, William, RIELY, Gregory J, ENGELMAN, Jeffrey A, KRIS, Mark G, JÄNNE, Pasi A, LYNCH, Thomas, JOHNSON, Bruce E, MILLER, Vincent A

“…Ten percent of North American patients with non-small-cell lung cancer have tumors with somatic mutations in the gene for the epidermal growth factor receptor…”
Get full text

Escaping ALK inhibition: mechanisms of and strategies to overcome resistance by Lovly, Christine M, Pao, William

“…Mutated anaplastic lymphoma kinase (ALK) drives the development of multiple tumor types, and ALK tyrosine kinase inhibitors such as crizotinib have been…”
Get more information

EML4-ALK: honing in on a new target in non-small-cell lung cancer by Horn, Leora, Pao, William

Get full text

Lung Adenocarcinoma From East Asian Never-Smokers Is a Disease Largely Defined by Targetable Oncogenic Mutant Kinases by Sun, Yihua, Ren, Yan, Fang, Zhaoyuan, Li, Chenguang, Fang, Rong, Gao, Bin, Han, Xiangkun, Tian, Weidong, Pao, William, Chen, Haiquan, Ji, Hongbin

“…To determine the proportion of lung adenocarcinomas from East Asian never-smokers who harbor known oncogenic driver mutations. In this surgical series, 52…”
Get full text

DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): A Catalog of Clinically Relevant Cancer Mutations to Enable Genome-Directed Anticancer Therapy by YEH, Paul, CHEN, Heidi, ANDREWS, Jenny, NASER, Riyad, PAO, William, HORN, Leora

“…Tumor gene mutation status is becoming increasingly important in the treatment of patients with cancer. A comprehensive catalog of tumor gene-response outcomes…”
Get full text